Novartis announced today that it intends to separate Sandoz into a new, publicly traded standalone company through a 100% spinoff. The spinoff of the generics and biosimilars division of Novartis aims to maximize shareholder value by creating the top European generics company and a global leader in biosimilars, according to a news release. Such a…
Novartis restarts production of radioligand therapy
Novartis announced recently that it has restarted radioligand therapy (RLT) production at two different sites. Basel, Switzerland-based Novartis on June 30 said that it restarted production in “early June” at its Ivrea, Italy, and Millburn, New Jersey, sites, according to a news release. The company had halted production in May due to what it cited…
Novartis mulls sale of $25 billion Sandoz generics arm
On the heels of announcing a restructuring plan that would do away with approximately 8,000 positions, Novartis AG (NYSE:NVS) is reportedly considering spinning off its Sandoz generics arm. The company is likely to make a final decision by the end of the year, according to Bloomberg. Given the sluggish state of the economy, Novartis is likely…
Novartis temporarily halts production of two radioligand therapy medicines
Novartis (NYSE:NVS) announced that it had voluntarily stopped the production at radioligand therapy plants in Ivrea, Italy and Millburn, New Jersey, over possible quality concerns. In a statement, the company explained it had made the decision “out of an abundance of caution due to potential quality issues identified in its manufacturing processes.” As a result,…
FDA approves Novartis’ Vijoice for to treat rare PROS genetic diseases
Novartis announced that it received FDA approval for its Vijoice (alpelisib) PIK3CA-Related Overgrowth Spectrum (PROS) treatment. Basel, Switzerland-based Novartis said in a news release that Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowth in blood vessel anomalies. FDA approval followed real-world evidence from the EPIK-P1 retrospective chart…
Novartis’ Sandoz, Ares Genetics seek better antibiotics deployment
Sandoz, a Novartis division, announced today that it extended and expanded a strategic collaboration agreement with Ares Genetics. Basel, Switzerland-baed Sandoz’s collaboration with Ares, aimed at driving innovation to develop solutions in the fight against antimicrobial resistance (AMR), was extended through January 31, 2025. According to a news release, the companies agreed to an extension…
Novartis partners with Carisma Therapeutics on manufacturing HER2-targeted CAR-M cell therapy
Novartis (NYSE:NVS) has inked a deal with the biopharma Carisma Therapeutics focused on the production of human epidermal growth factor receptor 2 (HER2)-targeted chimeric antigen receptor macrophages (CAR-M) to potentially treat solid tumors. Carisma is headquartered in Philadelphia. As part of the deal, Carisma will shift manufacturing to a Novartis cell therapy site in Morris…
Novartis to offer Ukraine-based humanitarian aid
Novartis (NYSE:NVS) is joining a growing number of pharma companies in supporting humanitarian efforts in Ukraine. The company recently announced an initial donation of $3 million to support Ukrainian humanitarian assistance initiatives at the International Red Cross and Red Crescent Movement, Save the Children and International Rescue Committee. Bayer and Roche have announced similar initiatives. Novartis also said…
Novartis to continue manufacturing Pfizer/BioNTech vaccine
Novartis (NYSE:NVS) has announced that it has reached an agreement with BioNTech (NSDQ:BNTX) and Pfizer (NYSE:PFE) to produce their popular COVID-19 BNT162b2 vaccine. The companies reached a new production agreement that will leave Novartis responsible for fill-and-finish operations related to the mRNA-based vaccine from Pfizer and BioNTech. Under the agreement, Novartis will produce at least…
10 of the best pharma companies to work for
The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research. The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries. To get a sense of which pharmaceutical companies…